Ignite Creation Date:
2025-12-24 @ 5:41 PM
Ignite Modification Date:
2025-12-30 @ 1:21 AM
Study NCT ID:
NCT01132768
Status:
TERMINATED
Last Update Posted:
2018-12-24
First Post:
2010-05-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Confirmatory Olmesartan Plaque Regression Study
Sponsor:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Organization:
Study Overview
Official Title:
Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study
Status:
TERMINATED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONFIRM
Brief Summary:
Effect of olmesartan medoxomil (20-40 mg) on plaque regression in hypertensive patients with carotid atherosclerosis.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: